SG11202001062XA - Compounds, salts thereof and methods for treatment of diseases - Google Patents
Compounds, salts thereof and methods for treatment of diseasesInfo
- Publication number
- SG11202001062XA SG11202001062XA SG11202001062XA SG11202001062XA SG11202001062XA SG 11202001062X A SG11202001062X A SG 11202001062XA SG 11202001062X A SG11202001062X A SG 11202001062XA SG 11202001062X A SG11202001062X A SG 11202001062XA SG 11202001062X A SG11202001062X A SG 11202001062XA
- Authority
- SG
- Singapore
- Prior art keywords
- diseases
- salts
- compounds
- treatment
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762548301P | 2017-08-21 | 2017-08-21 | |
| SE1730225 | 2017-08-24 | ||
| PCT/US2018/000354 WO2019040107A1 (en) | 2017-08-21 | 2018-08-20 | COMPOUNDS, CORRESPONDING SALTS AND METHODS FOR THE TREATMENT OF DISEASES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202001062XA true SG11202001062XA (en) | 2020-03-30 |
Family
ID=63840976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202001062XA SG11202001062XA (en) | 2017-08-21 | 2018-08-20 | Compounds, salts thereof and methods for treatment of diseases |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US11345693B2 (https=) |
| EP (2) | EP4635568A3 (https=) |
| JP (2) | JP7297738B2 (https=) |
| KR (1) | KR102692233B1 (https=) |
| CN (2) | CN117466803A (https=) |
| AU (1) | AU2018321546B2 (https=) |
| BR (1) | BR112020003477A2 (https=) |
| CA (1) | CA3071644A1 (https=) |
| DK (1) | DK3672954T3 (https=) |
| ES (1) | ES3042110T3 (https=) |
| FI (1) | FI3672954T3 (https=) |
| HU (1) | HUE073569T2 (https=) |
| IL (1) | IL272444B (https=) |
| LT (1) | LT3672954T (https=) |
| MX (1) | MX2020001757A (https=) |
| PL (1) | PL3672954T3 (https=) |
| PT (1) | PT3672954T (https=) |
| RS (1) | RS67273B1 (https=) |
| SG (1) | SG11202001062XA (https=) |
| SI (1) | SI3672954T1 (https=) |
| WO (1) | WO2019040107A1 (https=) |
| ZA (1) | ZA202001717B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202001062XA (en) | 2017-08-21 | 2020-03-30 | Acadia Pharm Inc | Compounds, salts thereof and methods for treatment of diseases |
| WO2019040104A2 (en) | 2017-08-21 | 2019-02-28 | Acadia Pharmaceuticals Inc. | COMPOUNDS, RELATED SALTS AND METHODS OF TREATING DISEASES |
| ES2906868T3 (es) * | 2019-05-22 | 2022-04-20 | Zakl Farmaceutyczne Polpharma S A | Intermedio farmacéutico para preparar pimavanserina |
| CA3130821A1 (en) | 2019-06-12 | 2020-12-17 | East China University Of Science And Technology | Antihypertensive polyol compound and derivative thereof |
| CN113214289B (zh) * | 2020-01-21 | 2022-10-28 | 瀚远医药有限公司 | 5-ht2a受体拮抗剂及其治疗中枢神经系统疾病的应用 |
| CN113214231B (zh) * | 2020-01-21 | 2022-04-08 | 瀚远医药有限公司 | 5ht2a受体拮抗剂及其医疗应用 |
| WO2021147818A1 (zh) * | 2020-01-21 | 2021-07-29 | 瀚远医药有限公司 | 5-ht2a受体拮抗剂及其治疗中枢神经系统疾病的应用 |
| CN113214141B (zh) * | 2020-01-21 | 2022-04-08 | 瀚远医药有限公司 | 5ht2a受体拮抗剂及其制备和应用 |
| CN115605202B (zh) | 2020-03-26 | 2025-10-28 | 盐野义制药株式会社 | 具有血清素受体结合活性的芳香族杂环衍生物 |
| CN111548257B (zh) * | 2020-05-28 | 2022-11-15 | 安道麦马克西姆有限公司 | 一种（4-异丙氧基-2-甲基）苯基异丙基酮的制备方法 |
| WO2022017440A1 (zh) * | 2020-07-22 | 2022-01-27 | 山东绿叶制药有限公司 | 5-ht 2a受体抑制剂或反向激动剂及其制备方法和应用 |
| US20240083872A1 (en) * | 2020-12-28 | 2024-03-14 | Shionogi & Co., Ltd. | Cyclic amine derivatives having serotonin receptor binding activity |
| CN113292484B (zh) * | 2021-06-04 | 2022-11-15 | 沈阳药科大学 | 3-(4-甲基哌啶-1-基)-3-苄基脲类化合物及其类似物、制备方法及应用 |
| AU2022326885A1 (en) * | 2021-08-11 | 2024-02-15 | Curadev Pharma Pvt. Ltd. | Small molecule urea derivatives as sting antagonists |
| AU2023319750A1 (en) * | 2022-08-03 | 2025-02-13 | Luye Innomind Pharma Shijiazhuang Co., Ltd. | 5-ht2a receptor inverse agonist, and preparation method therefor and use thereof |
| WO2024067304A1 (zh) * | 2022-09-28 | 2024-04-04 | 瀚远医药有限公司 | 一种具有Sigma2和5HT2A抑制活性的化合物及用途 |
| WO2024105007A1 (en) * | 2022-11-15 | 2024-05-23 | Samsara Therapeutics Inc. | Autophagy inducing compounds and uses thereof |
| KR20260048603A (ko) | 2023-08-02 | 2026-04-10 | 아카디아 파마슈티칼스 인코포레이티드 | 세로토닌-수용체 5-ht와 관련된 질환의 치료에서 사용하기 위한 3-(4-사이클로-프로폭시벤질)-1-(2,4-다이플루오로벤질)-1-(1-메틸피페리딘-4-일)유레아 |
| WO2025162237A1 (zh) * | 2024-02-02 | 2025-08-07 | 绿叶嘉奥制药石家庄有限公司 | 一种5-ht2a受体反向激动剂的盐型、晶型及其制备方法和应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1998A (en) | 1841-03-12 | Refrigerator | ||
| IL110298A (en) | 1993-07-13 | 1999-04-11 | Brann Mark Robert | Identification of ligands by selective amplification of cells transfected with receptors |
| FR2802206B1 (fr) * | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
| RU2002126554A (ru) | 2000-03-06 | 2004-03-20 | Акадиа Фармасьютикалз, Инк. (Us) | Азациклические соединения для применения при лечении опосредованных серотонином заболеваний |
| GB0108099D0 (en) * | 2001-03-30 | 2001-05-23 | Hoffmann La Roche | Aminopiperidine derivatives |
| CN100509804C (zh) | 2002-06-24 | 2009-07-08 | 阿卡蒂亚药品公司 | N-取代哌啶衍生物作为血清素受体试剂 |
| US7253186B2 (en) | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
| PT1587789E (pt) | 2003-01-16 | 2008-12-16 | Acadia Pharm Inc | Agonistas inversos selectivos para receptores 2a/2c da serotonina como agentes terapêuticos para doenças neurodegenerativas |
| JP4996467B2 (ja) * | 2004-09-27 | 2012-08-08 | アカディア ファーマシューティカルズ インコーポレイテッド | Ｎ−（４−フルオロベンジル）−ｎ−（１−メチルピペリジン−４−イル）−ｎ’−（４−（２−メチルプロピルオキシ）フェニルメチル）カルバミド、並びにその酒石酸塩及び結晶形態の合成 |
| US7790899B2 (en) * | 2004-09-27 | 2010-09-07 | Acadia Pharmaceuticals, Inc. | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
| GT200600042A (es) | 2005-02-10 | 2006-09-27 | Aventis Pharma Inc | Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a |
| ATE450262T1 (de) * | 2005-11-25 | 2009-12-15 | Galapagos Sas | Harnstoff-derivate als calcium-rezeptor- modulatoren |
| TW200831517A (en) | 2006-12-15 | 2008-08-01 | Astrazeneca Ab | Chemical compounds |
| WO2008141057A1 (en) * | 2007-05-08 | 2008-11-20 | Auspex Pharmaceuticals, Inc. | Deuterated pimavanserin 1- (4-flu0r0benzyl) -3- (4-isobutoxybenzyl) -1- ( l-methyl-piperidin-4-yl) -urea |
| KR100878446B1 (ko) | 2007-06-07 | 2009-01-13 | 일동제약주식회사 | 신규 펩티드 데포르밀라제 저해제 화합물 및 그 제조방법 |
| JP2010540454A (ja) | 2007-09-21 | 2010-12-24 | アカディア ファーマシューティカルズ，インコーポレーテッド | ピマバンセリンと他の薬剤との併用投与 |
| WO2009039461A2 (en) * | 2007-09-21 | 2009-03-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
| WO2010111353A1 (en) * | 2009-03-25 | 2010-09-30 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
| WO2012113103A1 (en) | 2011-02-25 | 2012-08-30 | Helsinn Healthcare S.A. | Asymmetric ureas and medical uses thereof |
| EP3082805B1 (en) | 2013-12-20 | 2020-02-05 | Institute for Drug Discovery, LLC | Substituted amino triazoles, and methods using same |
| CN104844502B (zh) | 2015-06-05 | 2018-07-31 | 齐鲁师范学院 | 一种匹莫范色林的制备方法 |
| PL3325444T3 (pl) | 2015-07-20 | 2021-12-06 | Acadia Pharmaceuticals Inc. | Sposoby wytwarzania N-(4-fluorobenzylo)-N-(1-metylopiperydyn-4-ylo)-N'-(4-(2-metylopropyloksy)fenylometylo)karbamidu oraz jego soli winianowej i postaci polimorficznej C |
| CN105481757A (zh) | 2015-12-25 | 2016-04-13 | 北京康立生医药技术开发有限公司 | 一种哌马色林的制备方法 |
| WO2019040104A2 (en) | 2017-08-21 | 2019-02-28 | Acadia Pharmaceuticals Inc. | COMPOUNDS, RELATED SALTS AND METHODS OF TREATING DISEASES |
| SG11202001062XA (en) | 2017-08-21 | 2020-03-30 | Acadia Pharm Inc | Compounds, salts thereof and methods for treatment of diseases |
-
2018
- 2018-08-20 SG SG11202001062XA patent/SG11202001062XA/en unknown
- 2018-08-20 SI SI201831265T patent/SI3672954T1/sl unknown
- 2018-08-20 EP EP25195295.8A patent/EP4635568A3/en active Pending
- 2018-08-20 FI FIEP18786069.7T patent/FI3672954T3/fi active
- 2018-08-20 CN CN202311171603.3A patent/CN117466803A/zh active Pending
- 2018-08-20 CA CA3071644A patent/CA3071644A1/en active Pending
- 2018-08-20 AU AU2018321546A patent/AU2018321546B2/en active Active
- 2018-08-20 EP EP18786069.7A patent/EP3672954B1/en active Active
- 2018-08-20 CN CN201880062080.XA patent/CN111132976B/zh active Active
- 2018-08-20 ES ES18786069T patent/ES3042110T3/es active Active
- 2018-08-20 WO PCT/US2018/000354 patent/WO2019040107A1/en not_active Ceased
- 2018-08-20 PT PT187860697T patent/PT3672954T/pt unknown
- 2018-08-20 MX MX2020001757A patent/MX2020001757A/es unknown
- 2018-08-20 LT LTEPPCT/US2018/000354T patent/LT3672954T/lt unknown
- 2018-08-20 JP JP2020510595A patent/JP7297738B2/ja active Active
- 2018-08-20 BR BR112020003477-0A patent/BR112020003477A2/pt unknown
- 2018-08-20 KR KR1020207006599A patent/KR102692233B1/ko active Active
- 2018-08-20 PL PL18786069.7T patent/PL3672954T3/pl unknown
- 2018-08-20 HU HUE18786069A patent/HUE073569T2/hu unknown
- 2018-08-20 DK DK18786069.7T patent/DK3672954T3/da active
- 2018-08-20 RS RS20250888A patent/RS67273B1/sr unknown
-
2020
- 2020-02-04 IL IL272444A patent/IL272444B/en unknown
- 2020-02-21 US US16/797,611 patent/US11345693B2/en active Active
- 2020-03-18 ZA ZA2020/01717A patent/ZA202001717B/en unknown
-
2022
- 2022-05-27 US US17/827,092 patent/US12139477B2/en active Active
-
2023
- 2023-06-14 JP JP2023097704A patent/JP7628578B2/ja active Active
-
2024
- 2024-09-27 US US18/900,015 patent/US20250197385A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272444A (en) | Compounds, their salts and methods for treating diseases | |
| ZA202006746B (en) | Methods of treatment | |
| IL264049A (en) | Compounds, preparations and methods for treating the disease | |
| ZA201800641B (en) | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | |
| IL264156A (en) | Compounds, preparations and methods for treating the disease | |
| IL253945A0 (en) | kdm1a inhibitors to treat the disease | |
| EP3212233A4 (en) | Combination therapy for treatment of disease | |
| HUE060671T2 (hu) | Eljárás fibrotikus betegségek kezelésére | |
| IL253244A0 (en) | Methods for treating retinal diseases | |
| HUE059303T2 (hu) | Acetilkolin-észteráz-gátlók bõrbetegségek kezelésére | |
| PT3273955T (pt) | Tratamento de doenças respiratórias | |
| ZA201906213B (en) | Compounds and methods for the treatment of parasitic diseases | |
| SI3210973T1 (sl) | Heteroarilne spojine za zdravljenje oftalmičnih bolezni | |
| EP3340974A4 (en) | METHODS OF TREATING DISEASES | |
| ZA201705877B (en) | Method of treating diseases | |
| IL253847A0 (en) | Methods of treating diseases | |
| HUE070257T2 (hu) | Vegyületek a lipofuscinhoz kapcsolódó betegségek kezelésére | |
| SG11202005850VA (en) | Methods of treatment of hypertrigl yceridemia | |
| PT3619204T (pt) | Compostos para o tratamento de doenças respiratórias | |
| IL259381B (en) | Mirabegron for the treatment of retinal diseases | |
| IL251135A (en) | A method for the synthesis of hydroxy-triglycerides and their use for disease prevention and treatment | |
| SG11202005278PA (en) | Compounds for treating eye diseases and methods thereof | |
| GB201500555D0 (en) | Method and device for the treatment of diseases | |
| EP3094330A4 (en) | Treatment of crohn's disease using low doses of laquinimod | |
| PL3638223T3 (pl) | Bromheksyna w leczeniu bólu |